Skip to main content
OpenTrials

Clinical trial condition

HIV-1 Infection

Explore clinical trials studying HIV-1 Infection. Study availability and eligibility vary by location and protocol.

182 public trials 1 recruiting study
Refine in advanced search Browse all conditions

HIV-1 Infection trial results

Completed

Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years

NCT02616783

Conditions
HIV-1 Infection
Locations
  • CHU Saint-Pierre University Hospital Brussels, Belgium
  • University Hospital Gent Ghent, Belgium
  • CHU - Groupe Saint-Andre Bordeaux, France
  • CHU de Dijon Dijon, France
View all 35 locations
View Trial Details
Completed

Safety and Biological Activity of Vesatolimod in HIV-1 Infected, Virologically Suppressed Adults

NCT02858401

Conditions
HIV-1 Infection
Locations
  • Mills Clinical Research Los Angeles, California, United States
  • UCSD Antiviral Research Center (AVRC) San Diego, California, United States
  • Midway Immunology & Research Center Ft. Pierce, Florida, United States
  • Orlando Immunology Center Recruiting Orlando, Florida, United States
View Trial Details
Completed

Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers

NCT02706717

Conditions
HIV-1 Infection
Locations
  • 31788 Alabama CRS Birmingham, Alabama, United States
  • UCLA CARE Center CRS (601) Los Angeles, California, United States
  • 701 University of California, San Diego AntiViral Research Center CRS San Diego, California, United States
  • 801 University of California, San Francisco HIV/AIDS CRS San Francisco, California, United States
View all 25 locations
View Trial Details
Completed

Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults

NCT02345226

Conditions
HIV-1 Infection
Locations
  • Maricopa Integrated Health System Phoenix, Arizona, United States
  • Spectrum Medical Group Phoenix, Arizona, United States
  • AHF Research Center Beverly Hills, California, United States
  • Pacific Oaks Medical Group Beverly Hills, California, United States
View all 117 locations
View Trial Details
Completed

Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)

NCT02345252

Conditions
HIV-1 Infection
Locations
  • The University of Alabama at Birmingham (UAB) Birmingham, Alabama, United States
  • Spectrum Medical Group Phoenix, Arizona, United States
  • AHF Research Center Beverly Hills, California, United States
  • Pacific Oaks Medical Group Beverly Hills, California, United States
View all 117 locations
View Trial Details

Related conditions